Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743413 | 1.00 | ADORA2A (0.61) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL638391 | 0.90 | PGK1 (0.66) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL743589 | 0.90 | NT5E (0.65) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL743588 | 0.90 | NT5E (0.65) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL638390 | 0.90 | PGK1 (0.66) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL8910495 | 0.90 | NT5E (0.65) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL17825912 | 0.87 | ADORA3 (0.79) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL639746 | 0.87 | ADORA3 (0.79) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL639745 | 0.87 | ADORA3 (0.79) | ADORA2AADORA3ADORA1TSHRNFKB1 | |
| SCHEMBL17824470 | 0.87 | ADORA3 (0.79) | ADORA2AADORA3ADORA1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-2430036-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130233-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | ADORA2A 111/4885ADORA3 363/4885ADORA1 340/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | ADORA2A 76/4885ADORA3 191/4885ADORA1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.